Détail de l'auteur
Auteur Europol |
Documents disponibles écrits par cet auteur (44)
Rapport
Europol ; L. LANIEL ; C. CARPENTIER ; J. MOUNTENEY ; B. PALLAVICINI ; L. ROYUELA ; J. MATIAS ; R. KASECKER ; R. SEDEFOV ; P. GRIFFITHS | Lisbon : OEDT / EMCDDA | Joint publications | 2011FRANÇAIS : L'OEDT et Europol publient une analyse conjointe concernant le marché des amphétamines. Leader dans la production des amphétamines, l'Europe est également une zone importante de consommation. ENGLISH: This joint publication with [...]Rapport
Drug matters appear high on the political agenda of the European Union. In the last decade, two successive European Union Drug Strategies and their related Action Plans were endorsed and implemented. In the area of synthetic drugs, a specific Ac[...]Rapport
Europol ; L. LANIEL ; C. CARPENTIER ; C. COSTA STORTI ; A. GALLEGOS ; D. LOPEZ ; C. MARTEL ; L. ROYUELA ; R. SEDEFOV ; R. SIMON ; J. WRIGHT ; F. ZOBEL ; P. GRIFFITHS | Lisbon : OEDT / EMCDDA | Joint publications | 2010This report provides an overview of what is known about how cocaine is produced and trafficked into the European Union. It aims to provide a better understanding of the actors involved, the routes taken, and the scale of the problem in Europe. I[...]Rapport
This report delves into the activities of these criminals and their methods. Drug trafficking operations benefit from a number of different actors, such as brokers, cooks, envoys, intermediaries, and money laundering service providers. Examples [...]Rapport
This joint report prepared by the EMCDDA and Europol considers the latest findings from international research, fresh empirical data, and operational information and intelligence in order to illuminate how darknet markets function and how they r[...]Rapport
L. A. KING ; R. SEDEFOV ; Europol | Lisbon : OEDT / EMCDDA | Risk assessments, ISSN 1725-4493 | 2007ENGLISH : The purpose of these guidelines is to address the measures introduced by Council Decision 2005/387/HA. They are concerned only with the first stage, i.e. the early-warning system and information exchange, and replace the earlier guid[...]Rapport
FRANÇAIS : Les nouvelles drogues officiellement signalées à l'OEDT et à Europol en 2009 via le système d'alerte précoce de l'UE sur les nouvelles substances psychoactives (Early-warning system/EWS) ont atteint un chiffre record. C'est ce qui se[...]Rapport
FRANÇAIS : De nouvelles substances psychoactives deviennent largement disponibles à un « rythme sans précédent ». En 2010, un nombre record de nouvelles drogues ont été officiellement signalées à l'OEDT et à Europol par le biais du système d'al[...]Rapport
FRANÇAIS : De nouvelles drogues ont été détectées dans l'Union européenne l'année dernière, à raison d'une par semaine environ, selon le rapport annuel conjoint de l'OEDT et d'Europol (2011) sur les nouvelles substances psychoactives publié auj[...]Rapport
FRANÇAIS : Le rapport annuel 2013 OEDT-Europol, qui fait le point sur les nouvelles drogues, indique que le nombre, le type et la disponibilité des nouvelles drogues en Europe ont continué à croître en 2012. Elles étaient au nombre de 49 en 201[...]Rapport
This report presents the key activities performed by the EMCDDA and Europol in 2013, with details on all the relevant activities in support of the implementation of Council Decision 2005/387/JHA on the information exchange, risk assessment and c[...]Rapport
This report presents the key activities performed by the EMCDDA and Europol in 2014, with details on all the relevant activities in support of the implementation of Council Decision 2005/387/JHA on the information exchange, risk assessment and c[...]Rapport
This report presents the key activities performed by the EMCDDA and Europol in 2017 and the results of the implementation of Council Decision 2005/387/JHA on the information exchange, risk assessment and control of new psychoactive substances, i[...]Rapport
In March 2017, the EMCDDA and Europol examined the available information on the new psychoactive substance 1-(4-cyanobutyl)-N-(2-phenylpropan-2-yl)indazole-3-carboxamide, commonly known as CUMYL-4CN-BINACA, through a joint assessment. The two or[...]Rapport
In April 2014, the EMCDDA and Europol examined the available information on a new psychoactive substance 1-cyclohexyl-4-(1,2-diphenylethyl)piperazine, commonly known as MT-45. The two organisations concluded that sufficient information had been [...]Rapport
In May 2015, the EMCDDA and Europol examined the available information on a new psychoactive substance 1-phenyl-2-(1-pyrrolidinyl)-1-pentanone, commonly known as alpha-pyrrolidinovalerophenone (alpha-PVP), through a joint assessment. The two org[...]Rapport
In September 2017, the EMCDDA and Europol examined the available information on the new psychoactive substance 2-methoxy-N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]acetamide (methoxyacetylfentanyl), through a joint assessment. The two organisat[...]Rapport
The EMCDDA-Europol Joint Report on new psychoactive substance 4-iodo-2,5-dimethoxy-N-(2-methoxybenzyl)phenethylamine, commonly known by the abbreviation '25I-NBOMe', submitted in December 2013 to the Council of the EU, the European Commission an[...]Rapport
In February 2014, the EMCDDA and Europol examined the available information on a new psychoactive substance, 4-methyl-5-(4-methylphenyl)-4,5-dihydrooxazol-2-amine (commonly known by the abbreviation 4,4′-DMAR). The two organisations concluded th[...]Rapport
At the end of 2011 and in 2012, the EMCDDA and Europol examined the available information on a new psychoactive substance, 4-methylamphetamine. The two organisations concluded that sufficient information had been accumulated to merit the product[...]Rapport
At the end of September 2012, the EMCDDA and Europol examined the available information on a new psychoactive substance 5-(2-aminopropyl)indole (commonly known by the abbreviation '5-IT'), through a joint assessment. The two organisations conclu[...]Rapport
The EMCDDA-Europol Joint Report on new psychoactive substance AH-7921 (3,4-dichloro-N-[[1-(dimethylamino)cyclohexyl]methyl]benzamide), submitted in December 2013 to the Council of the EU, the European Commission and the EMA. After assessing the [...]Rapport
The EMCDDA-Europol Joint Report on new psychoactive substance MDPV (3,4-methylenedioxypyrovalerone), submitted in December 2013 to the Council of the EU, the European Commission and the EMA. After assessing the available evidence, the EMCDDA and[...]Rapport
The EMCDDA-Europol Joint Report on new psychoactive substance methoxetamine (2-(3-methoxyphenyl)-2-(ethylamino)cyclohexanone), submitted in December 2013 to the Council of the EU, the European Commission and the EMA. After assessing the availabl[...]Rapport
In May 2017, the EMCDDA and Europol examined the available information on the new psychoactive substance methyl 1-(2-phenylethyl)-4-[phenyl(propanoyl)amino]piperidine-4-carboxylate (carfentanil), through a joint assessment. The two organisations[...]Rapport
In March 2017, the EMCDDA and Europol examined the available information on the new psychoactive substance methyl 2-{[1-(5-fluoropentyl)-1H-indazole-3-carbonyl]amino}-3,3-dimethylbutanoate, commonly known as 5F-MDMB-PINACA, through a joint asses[...]Rapport
In February 2016, the EMCDDA and Europol examined the available information on a new psychoactive substance methyl 2-[[1-(cyclohexylmethyl)indole-3-carbonyl]amino]-3,3-dimethylbutanoate, commonly known as MDMB-CHMICA, through a joint assessment.[...]Rapport
In March 2017, the EMCDDA and Europol examined the available information on the new psychoactive substance N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1- (cyclohexylmethyl)-1H-indazole-3-carboxamide, commonly known as ADB-CHMINACA, through a joint [...]Rapport
In March 2017, the EMCDDA and Europol examined the available information on the new psychoactive substance N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)- 1H-indazole-3-carboxamide, commonly known as AB-CHMINACA, through a joint asses[...]Rapport
In September 2016, the EMCDDA and Europol examined the available information on a new psychoactive substance N-(1-phenethylpiperidin-4-yl)-N-phenylacrylamide, commonly known as acryloylfentanyl, through a joint assessment. The two organisations [...]Rapport
In March 2017, the EMCDDA and Europol examined the available information on the new psychoactive substance N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl) isobutyramide, commonly known as 4-fluoroisobutyrylfentanyl (4F-iBF), through a joint ass[...]Rapport
In September 2015, the EMCDDA and Europol examined the available information on a new psychoactive substance N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]acetamide (acetylfentanyl), through a joint assessment. The two organisations concluded that[...]Rapport
In September 2017, the EMCDDA and Europol examined the available information on the new psychoactive substance N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]cyclopropanecarboxamide (cyclopropylfentanyl), through a joint assessment. The two organis[...]Rapport
In March 2017, the EMCDDA and Europol examined the available information on the new psychoactive substance N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]tetrahydrofuran-2-carboxamide, commonly known as tetrahydrofuranylfentanyl (THF-F), through a [...]Document multimédia
"EU Drug Market: Amphetamine" describes the European amphetamine market from production and trafficking, to distribution and use. It details the processes, materials and actors involved at different stages and levels of the market. Taking a thre[...]Rapport
This resource offers a strategic and top-level summary for policymakers and decision-makers, to support the development and implementation of policies and actions in Europe, based on a robust understanding of the current drug landscape and emerg[...]Document multimédia
'EU Drug Market: Cannabis' describes the European cannabis market from production and trafficking, to distribution and use. It details the processes, materials and players involved at different stages and levels of the market. The module takes a[...]Rapport
Document multimédia
What are the latest changes in the EU opioids market? How are global geopolitical developments impacting supply? Are heroin trafficking routes changing? To what extent do synthetic opioids pose a threat to Europe? These are among the issues expl[...]Rapport
What effect is COVID-19 having on the drug market in the EU? This joint publication from the EMCDDA and Europol analyses the impact of the pandemic on the market for the main drug types (cannabis, heroin, cocaine, amphetamines, NPS), including d[...]Rapport
Rapport
The EU Drug Markets Report 2019 is the third comprehensive overview of illicit drug markets in the European Union by the EMCDDA and Europol. The analysis presented in this report spans numerous topics such as the links between drugs and other cr[...]Rapport
FRANÇAIS : Le présent rapport analyse le phénomène du marché des drogues illicites dans le contexte plus large des nouvelles tendances en matière de consommation de drogue, des facteurs culturels et sociaux et des liens avec la criminalité. Les[...]Rapport
The EU drug markets report is the first comprehensive overview of illicit drug markets in the European Union. It covers issues such as production, consumer markets, trafficking, organised crime and policy responses, along with a review of the ma[...]